---
source_pdf: "https://drive.google.com/file/d/1r5lYajBJBalVBzWmzOjnHgjdEDMn1IKn/view"
drive_folder: "Portfolio/Ryght/Ryght - Data Room/3. Commercial/NDAs"
type: portfolio
company: Ryght
ingested: 2025-12-27
original_filename: "CDA_Trace Biosciences, Inc._.pdf"
---

> **Original:** [View Original PDF](https://drive.google.com/file/d/1r5lYajBJBalVBzWmzOjnHgjdEDMn1IKn/view)

DocuSign Envelope ID: EA8AAD30-BE0A-4E3B-9D23-B7F6DE857DB4

# CONFIDENTIAL

## TWO-WAY NONDISCLOSURE AGREEMENT

This Two-Way Nondisclosure Agreement (this “Agreement”) is made and entered into as of February 25th, 2024 (“Effective Date”) between Trace Biosciences, Inc. (“Trace”), with a principal place of business at 4640 SW Macadam Ave., Suite 270, Portland, OR 97239 and Ryght, Inc. (“Ryght”) with a principal place of business at 1950 W. Company Way, #12489, Anaheim, CA 92801. As used herein, the party disclosing information is the “Discloser” and the party receiving the information is the “Recipient".

1.  **Purpose.** Discloser and Recipient have a business relationship of mutual interest related to generative artificial intelligence in clinical development with respect to Ryght and Trace to the intended discussion/transaction/information] (the “Purpose”) which Discloser desires Recipient to treat as confidential.

2.  **Confidential Information.** “Confidential Information” means any information not generally known or proprietary disclosed to Recipient or its Representatives (as defined below) by Discloser or its Affiliates (or on behalf of Discloser or its Affiliates), either directly or indirectly in writing, orally or by inspection of tangible objects, including without limitation documents, prototypes, samples, materials, sequences, structures, results, data and know-how, trade secrets, product composition, product properties and specifications, formulations, processes and methodologies, current and planned manufacturing, testing and regulatory requirements, labeling, storage and distribution, equipment, plans, designs, business models, reports, and intellectual property. Confidential Information of both parties also includes the existence of this Agreement, the terms and conditions hereof and the fact that the parties are evaluating the other party's Confidential Information. All information disclosed from Discloser to Recipient shall be deemed Confidential Information; provided that, information that satisfies any of the exceptions in accordance with Section 5 below shall not be deemed Confidential Information.

3.  **Non-use and Non-disclosure.** During the term of the Agreement, Recipient agrees to keep the Confidential Information confidential and shall not use any Confidential Information for any purpose except to evaluate or to fulfill the Purpose. Recipient shall not disclose any Confidential Information to third parties except to agents, Affiliates, consultants, sub-contractors and/or employees, attorneys, accountants and financial advisors of Recipient ("Representatives") on a "need-to-know" basis; provided that such Representatives agree to be bound by confidentiality and use obligations no less restrictive than those set forth in this Agreement. Furthermore, the Recipient agrees to be responsible for any violations of this Agreement by its respective Representatives. Unless mutually agreed in writing by both parties, Recipient shall not re-create, reverse engineer, disassemble or decompile any sequences, structures, samples, materials, prototypes, software or other tangible objects which embody Discloser's Confidential Information and which are provided to Recipient hereunder. "Affiliate” as used herein shall mean a corporation or other entity that directly or indirectly controls or is controlled by or is under common control with a party to this Agreement where “control” means the ownership of at least fifty percent (50%) of the voting share capital of an entity or any other comparable equity or ownership interest.

4.  **Maintenance of Confidentiality.** Recipient agrees that it shall take all reasonable measures to protect the secrecy of and avoid disclosure and unauthorized use of the Discloser's Confidential Information. Recipient agrees that it will (and shall compel each and any of its Representatives that receive any Confidential Information of the Discloser to) keep Discloser's Confidential Information confidential and will not disclose the Confidential Information to any person except with the specific prior written consent of the Discloser or as expressly permitted by the terms of this Agreement. Recipient shall not make any copies of Confidential

Page 1 of 5
$19a2822dd680$FA647174F55444F6ACA187897B218AAC.docx

DocuSign Envelope ID: EA8AAD30-BE0A-4E3B-9D23-B7F6DE857DB4

# CONFIDENTIAL

Information (with the exception of copies to Representatives) unless the same are previously approved in writing by the Discloser. Recipient shall appropriately mark Discloser's proprietary rights notices on any such approved copies. Recipient shall promptly notify Discloser in the event of any unauthorized use or disclosure of the Confidential Information by it or its Representatives.

5.  **Exceptions.** The obligations of the Recipient and its Representatives under this Agreement will not apply to such Confidential Information, if the Recipient can demonstrate by written or other competent evidence that the Confidential Information:
    (i) was, at the time of its disclosure in the public domain, or subsequently entered the public domain through no breach of this Agreement;
    (ii) was in the Recipient's possession at the time of its disclosure hereunder;
    (iii) was lawfully acquired by the Recipient from a third party who has legal right to disclose such information; or
    (iv) was independently developed by or on behalf of the Recipient without reference to or use of or reliance upon any Confidential Information received from the Discloser.
    Notwithstanding the above, specific Confidential Information of the Discloser shall not be deemed or assumed to be within the foregoing exceptions merely because it is embraced or covered by (i) partial or more general information in the public domain or (ii) partial or more general information in the possession of the Recipient, or (iii) a combination of (i) and/or (ii). In addition, any combination of information shall not be deemed or assumed to be within the foregoing exceptions merely because all individual parts of such information are in the public domain or in the possession of the Recipient.

6.  **Permitted Disclosure.** The Recipient may disclose or submit the Discloser's Confidential Information to the extent required by applicable laws or regulations (including applicable regulations of an admitted stock exchange), or by the order of a competent court, government agency or stock exchange supervisory authority provided, however, that the Recipient shall provide the Discloser with written notice as soon as may be practicable and legally permissible so that the latter may contest such potential submission or disclosure and provided further that the Recipient will reasonably cooperate with the Discloser's efforts to seek a protective order or similar privilege available under the applicable law if requested by, and at the expense of, the Discloser. Each party agrees that it shall comply and act in accordance with all applicable provisions of federal and state laws and regulations concerning such Confidential Information. Any Confidential Information disclosed pursuant to permitted disclosures under this Section shall not lose its status as Confidential Information by virtue of such disclosure.

7.  **No Obligation.** Nothing herein shall obligate Discloser or Recipient to proceed with any transaction between them or to enter into any further agreement, and each party reserves the right, in its sole discretion, to terminate the discussions contemplated by this Agreement.

8.  **No Warranty.** ALL CONFIDENTIAL INFORMATION IS PROVIDED “AS IS” WITH NO WARRANTIES, WHETHER EXPRESS OR IMPLIED, ARISING BY LAW OR OTHERWISE, INCLUDING, BUT NOT LIMITED TO, ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, VALUE, COMPLETENESS, PERFORMANCE, NON-INFRINGEMENT OF THE PATENT RIGHTS OF ANY THIRD PARTY, OR OTHERWISE.

Page 2 of 5
$19a2822dd680$FA647174F55444F6ACA187897B218AAC.docx

DocuSign Envelope ID: EA8AAD30-BE0A-4E3B-9D23-B7F6DE857DB4

# CONFIDENTIAL

9.  **Return of Materials and Information.** All documents and other tangible objects containing or representing Discloser's Confidential Information and all copies thereof which are in the possession of Recipient shall be and remain the property of Discloser and shall be promptly returned to Discloser or destroyed upon Discloser's request, except for a single copy thereof which may be retained by Recipient for the sole purpose of determining the scope of obligations incurred under this Agreement. In addition, upon Discloser's written request, the Recipient shall destroy any Confidential Information of the Discloser which is in electronic form or cannot otherwise be returned to the Discloser, however, nothing shall require the alteration, modification, deletion or destruction of back-up media made in the ordinary course of business or in accordance with a party's records retention and destruction policies, provided that said back-up media shall be stored in a manner that prevents unauthorized access to or use of Confidential Information of the other party.

10. **No License.** Nothing in this Agreement is intended to grant any rights, expressed or implied, to Recipient under any patent, trade secret, mask work right, copyright or other intellectual property rights of Discloser, nor shall this Agreement grant Recipient any rights in or to Confidential Information or any information of third parties, except as expressly set forth herein.

11. **Term.** Unless prior terminated, this Agreement shall become effective as of the Effective Date and remain in full force and effect for a period of two (2) year thereafter (the “Term"). Either party may terminate this Agreement, for any reason or for no reason, upon fifteen (15) days prior written notice to the other party but any such early termination will have no effect on the parties' continuing obligations of confidentiality and non-use. Notwithstanding such expiration or termination, the obligations of the Recipient specified herein shall continue with respect to the Confidential Information until the fifth (5th) anniversary of the termination or expiration hereunder; provided, however, that any obligations with regard to Confidential Information identified as "trade secret" by the Discloser shall continue until such Confidential Information ceases to be a trade secret under applicable law.

12. **Remedies.** The Recipient acknowledges and agrees that (i) the Confidential Information is commercially sensitive, proprietary and valuable to the Discloser; (ii) damages may not be available, or if they are, may not be an adequate remedy for the Discloser; (iii) any breach or threatened breach of this Agreement may cause irreparable injury to the Discloser; and (iv) in addition to seeking any other remedies available at law or in equity, the Discloser is entitled to seek injunctive relief as a remedy for any breach or threatened breach of this Agreement. In the event of any legal proceeding between the Discloser and Recipient arising out of or related to this Agreement, the prevailing party shall be entitled to recover, in addition to any other relief award or granted, its costs and expenses (including reasonable attorneys' fees and expert witness' fees) incurred in any such proceeding.

13. **Miscellaneous.** (a) This Agreement (i) may not be assigned or transferred, in whole or in part, by either party without the prior written consent of the other party, provided, however, either party may transfer or assign this Agreement, in whole or in part, without the prior written consent of the other party, to an Affiliate or in connection with a merger, consolidation, or a sale or transfer of all or substantially all of the assets to which this Agreement relates; and (ii) shall bind and inure to the benefit of the parties hereto and their successors and assigns. (b) This Agreement shall be governed by the laws of the State of Oregon, without reference to conflict of laws principles. Any action or proceeding brought to enforce the terms of this Agreement shall be brought in the State of Oregon, County of Multnomah. (c) This document contains the entire agreement between the parties with respect to the subject matter hereof and supersedes any and all prior written agreements, oral discussions, or understandings between them with respect to the Purpose. (d) No waiver of any provision of

Page 3 of 5
$19a2822dd680$FA647174F55444F6ACA187897B218AAC.docx

DocuSign Envelope ID: EA8AAD30-BE0A-4E3B-9D23-B7F6DE857DB4

# CONFIDENTIAL

this Agreement shall constitute a waiver of any other provision(s) or of the same provision on another occasion. Any failure to enforce any provision of this Agreement shall not constitute a waiver thereof or of any other provision hereof. (e) Each party represents it has the right to enter into this Agreement and to disclose the Confidential Information and that such disclosure does not violate any other third-party contracts it may have. (f) Neither party shall use the name of the other party or make any oral or written release of any statement, information, advertisement or press release having any reference to a party, whether express or implied, without the express prior written approval of that party; except where required by law. (g) This Agreement may not be amended, nor any obligation waived, except by a writing signed by both parties hereto. (h) In the event that any provision of this Agreement shall, for any reason, be held to be invalid or unenforceable in any respect, such invalidity or unenforceability shall not affect any other provision of this Agreement, and this Agreement shall be construed as if such invalid or unenforceable provision had not been included in this Agreement.

14. **Counterparts.** This Agreement may be signed in counterparts, each and every one of which shall be deemed an original and part of the same instrument. Facsimile, electronic, and scanned signatures shall be treated as original signatures.

[Remainder of page intentionally left blank. / Signature page follows.]

Page 4 of 5
$19a2822dd680$FA647174F55444F6ACA187897B218AAC.docx

DocuSign Envelope ID: EA8AAD30-BE0A-4E3B-9D23-B7F6DE857DB4

# CONFIDENTIAL

IN WITNESS WHEREOF, the parties have executed this Agreement through their authorized signatories with effect from the Effective Date.

**Trace Biosciences, Inc.**
By: B._
DocuSign -30B7DD7B552840D...
Name: Connor W. Barth, Ph.D.
Title: President and CEO
Date: 2/26/2024

**Ryght, Inc.**
DocuSign Signed by:
By: Tyrone Richardson
D164DAB8566447E...
Name: Tyrone Richardson
Title: Chief Commercial Officer
Date: 2/25/2024

Page 5 of 5
$19a2822dd680$FA647174F55444F6ACA187897B218AAC.docx